期刊
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
卷 23, 期 10, 页码 793-811出版社
ZHEJIANG UNIV PRESS
DOI: 10.1631/jzus.B2200256
关键词
Chimeric antigen receptor-T (CAR-T); B-cell malignancies; Mechanisms of relapse; Strategy
类别
资金
- National Natural Science Foundation of China [81730008]
This review discusses the challenges of relapse after CAR-T cell therapy in B-cell malignancies. The factors contributing to relapse include intrinsic factors of tumor cells and the unique construction of CAR-T cells, while complex interactions among CAR-T cells, tumor cells, and the tumor microenvironment also affect efficacy and persistence.
Chimeric antigen receptor-T (CAR-T) cell therapy, as a novel cellular immunotherapy, has dramatically reshaped the landscape of cancer treatment, especially in hematological malignancies. However, relapse is still one of the most troublesome obstacles to achieving broad clinical application. The intrinsic factors and superior adaptability of tumor cells mark a fundamental aspect of relapse. The unique biological function of CAR-T cells governed by their special CAR construction also affects treatment efficacy. Moreover, complex cross-interactions among CAR-T cells, tumor cells, and the tumor microenvironment (TME) profoundly influence clinical outcomes concerning CAR-T cell function and persistence. Therefore, in this review, based on the most recent discoveries, we focus on the challenges of relapse after CAR-T cell therapy in B-cell malignancies from the perspective of tumor cells, CAR-T cells, and the TME. We also discuss the corresponding basic and clinical approaches that may overcome the problem in the future. We aim to provide a comprehensive understanding for scientists and physicians that will help improve research and clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据